Trial Profile
A Single Centre Study of Pharmacokinetics and Safety of NOX66 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2020
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary)
- Indications Diffuse intrinsic pontine glioma; Nasopharyngeal cancer; Prostate cancer; Septic shock; Solid tumours
- Focus Pharmacokinetics
- Sponsors Noxopharm
- 02 Dec 2020 Status changed from recruiting to completed.
- 09 Jan 2020 New trial record